Explore a selection of our essential drug information below, or:
Identification
- Summary
Hydroxyethyl Starch is a plasma volume substitute used to treat and prevent hypovolemia.
- Brand Names
- Hespan, Hextend, Volulyte, Voluven
- Generic Name
- Hydroxyethyl Starch
- DrugBank Accession Number
- DB09106
- Background
Hydroxyethyl starch (HES/HAES) is a nonionic starch derivative. Hydroxyethyl starches (HES) are synthetic colloids commonly used for fluid resuscitation to replace intravascular volume. HES is a general term and can be sub-classified according to average molecular weight, molar substitution, concentration, C2/C6 ratio and Maximum Daily Dose.
- Type
- Small Molecule
- Groups
- Approved
- Synonyms
- HAES
- HES
- Hetastarch
- Hydroxyethylstarch
Pharmacology
- Indication
An intravenous solution of hydroxyethyl starch is used to prevent shock following severe blood loss caused by trauma, surgery, or other issues.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Prophylaxis of Hypovolemia •••••••••••• Treatment of Hypovolemia •••••••••••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
After isovolemic exchange of blood with 500 mL of HES in healthy volunteers, blood volume is maintained for at least 6 hours
- Mechanism of action
Hydroxyethyl starch (HES) is one of the most frequently used plasma substitutes. Recent studies have indicated that HES may reduce capillary leakage.
- Absorption
Peak concentration (C(max), 4.34 mg/mL)
- Volume of distribution
5.9 L.
- Protein binding
Data not found.
- Metabolism
When given intravenously, molecules smaller than the renal threshold (60,000-70,000 daltons) are readily and rapidly excreted in the urine, while molecules with higher molecular weights are metabolized by plasma α-amylase prior to excretion via the renal route.
- Route of elimination
Approximately 62 % of HES was excreted as hydroxyethyl starch molecules in urine within 72 hours.
- Half-life
Terminal half-life is 16.1 h. Elimination half-life is 12 h.
- Clearance
31.4 mL/min
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
LDF50 (IV, rabbit): 8460 mg/Kg.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Abacavir may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level. Acetaminophen Acetaminophen may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Hydroxyethyl Starch which could result in a lower serum level and potentially a reduction in efficacy. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Hextend Injection, solution 6 g/100mL Intravenous Hospira, Inc. 2005-02-02 Not applicable US 
Hextend Solution 6 g / 100 mL Intravenous Biotime Inc 2003-12-11 2013-07-12 Canada 
Truemed Group LLC Liquid 10 g/1000mL Intravenous Truemed Group LLC 2022-09-17 Not applicable US Volulyte Solution 6 % Intravenous Fresenius Kabi 2011-05-16 Not applicable Canada Voluven Solution 6 % Intravenous Fresenius Kabi 2006-09-18 Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image 6% Hetastarch In 0.9% Sodium Chloride Injection, solution 6 g/100mL Intravenous HF Acquisition Co LLC, DBA HealthFirst 2018-11-26 Not applicable US Hetastarch Injection 6 g/100mL Intravenous Teva Parenteral Medicines, Inc. 2009-01-13 2014-09-30 US Hetastarch in Sodium Chloride Injection, solution 6 g/100mL Intravenous Hospira, Inc. 2005-02-28 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Hespan Hydroxyethyl Starch (6 g/100mL) + Sodium chloride (0.9 g/100mL) Injection, solution Intravenous B. Braun Medical Inc. 1991-04-04 Not applicable US Hespan Hydroxyethyl Starch (6 g/100mL) + Sodium chloride (0.9 g/100mL) Injection, solution Intravenous Cardinal Health 1991-04-04 2016-03-31 US Hydroxyethyl Starch in Sodium Chloride Hydroxyethyl Starch (6 g/100mL) + Sodium chloride (900 mg/100mL) Injection, solution Intravenous B. Braun Medical Inc. 2015-01-09 Not applicable US HYPERHAES INT. INF. ICIN COZELTI Hydroxyethyl Starch (6 %) + Sodium chloride (7.2 %) Solution Intravenous FRESENİUS KABİ İLAÇ SAN. VE TİC. LTD. ŞTİ. 2009-06-10 2019-07-16 Turkey 
NEOHES %6 HES % 0.9 SODYUM KLORÜR İV İNFÜZYON İÇİN ÇÖZELTİ, 500 ML SETLİ Hydroxyethyl Starch (60 g/1000ml) + Sodium chloride (9 g/1000ml) Injection, solution Intravenous TURKTIPSAN SAĞLIK TURİZM EĞİTİM VE TİC. A.Ş. 2020-08-14 Not applicable Turkey - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image BIOHES %10 INTRAVENOZ 500 ML SOLUSYON SETLI SISE Hydroxyethyl Starch (10 %) Solution Intravenous OSEL İLAÇ SAN. VE TİC. A.Ş. 2018-12-25 Not applicable Turkey BIOHES %10 INTRAVENOZ 500 ML SOLUSYON SETSIZ SISE Hydroxyethyl Starch (10 %) Solution Intravenous OSEL İLAÇ SAN. VE TİC. A.Ş. 2018-12-25 Not applicable Turkey BIOHES %6 INTRAVENOZ 500 ML SOLUSYON SETSIZ SISE Hydroxyethyl Starch (6 %) Solution Intravenous OSEL İLAÇ SAN. VE TİC. A.Ş. 2018-12-25 Not applicable Turkey ISOHES %6 (SETLI) 500 ML SOLUSYON Hydroxyethyl Starch (6 %) + Sodium chloride (0.9 %) Solution Intravenous ECZACIBAŞI-BAXTER HASTANE ÜRÜNLERİ SAN.VE TİC. A.Ş. 2013-01-29 2024-01-23 Turkey ISOHES %6 (SETSIZ)500 ML SOLUSYON Hydroxyethyl Starch (6 %) + Sodium chloride (0.9 %) Solution Intravenous ECZACIBAŞI-BAXTER HASTANE ÜRÜNLERİ SAN.VE TİC. A.Ş. 2013-01-29 2024-01-23 Turkey
Categories
- ATC Codes
- B05AA07 — Hydroxyethylstarch
- Drug Categories
- Blood and Blood Forming Organs
- Blood and Related Products
- Blood Substitutes
- Blood Substitutes and Perfusion Solutions
- Blood Substitutes and Plasma Protein Fractions
- Carbohydrates
- Compounds used in a research, industrial, or household setting
- Dietary Carbohydrates
- Drugs that are Mainly Renally Excreted
- Glucans
- Hematologic Agents
- Increased Intravascular Volume
- Osmotic Activity
- Plasma Substitutes
- Polysaccharides
- Replacement Preparations
- Starch
- Classification
- Not classified
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 875Y4127EA
- CAS number
- 9005-27-0
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
References
- General References
- External Links
- KEGG Drug
- D03335
- PubChem Substance
- 347910407
- 5531
- ChEMBL
- CHEMBL2108448
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Completed Not Available Acute Kidney Injury After Adult Cardiac Surgery 1 somestatus stop reason just information to hide Not Available Completed Not Available Avascular Necrosis of Hip / Total Hip Replacement Arthroplasty 1 somestatus stop reason just information to hide Not Available Completed Not Available Cardiac Surgical Procedures (D006348) 1 somestatus stop reason just information to hide Not Available Completed Not Available Hypotension / Shock 1 somestatus stop reason just information to hide Not Available Completed Not Available Hypovolaemia / Impaired Oxygen Delivery / Output, Low Cardiac 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Intravenous 6.00 g Solution Intravenous 10 % Injection Intravenous Injection, solution Intravenous Solution Parenteral 10.000 g Solution Intravenous 6.000 g Injection Intravenous 6 g/100mL Injection, solution Intravenous 6 g/100mL Solution Intravenous 6 g / 100 mL Injection, solution Intravenous Solution Intravenous Solution Intravenous 0.3675 g/1000ml Liquid Intravenous 10 g/1000mL Injection, solution Intravenous 6 % Solution Solution Intravenous 6 % Solution Parenteral Injection Intravenous 60 g/l Injection, solution Intravenous 10 % - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at September 16, 2015 22:43 / Updated at October 07, 2024 13:58